This is a new guideline from Nice recommending that omalizumab can be considered in chronic urticaria.
Apparently it is already being used on occasion, though due to cost, it is more common for immunosuppressants like ciclosporin to be used. Omalizumab is preferred because of less need for monitoring.
It is not disease modifying and repeat courses are likely to be required.
There are criteria for its use (ie the urticaria must be severe and not have responded to antihistamines or leukotriene receptor antagonists). It is obviously specialist use only.